NTNatalia A. Totolyan

Natalia A. Totolyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia A. Totolyan has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

    by V. S. Krasnov, Ya. V. Vlasov, E. Р. Evdoshenko, D. S. Korobko, V. М. Lebedev, I. G. Lukashevich, A. I. Nilov, E. S. Novikova, E. V. Popova, K. V. Sapozhnikov, et al.

    Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory diseases of the central nervous system. B-lymphocytes play leading role in their pathogenesis in most cases. СD20 surface antigen is one of the B-lymphocytes makers. There is extensive world experience with chimeric monoclonal anti-CD20 antibody rituximab off-label using for NMOSD exacerbations prevention. It has been included in published international and Russian algorithms for NMOSD treatment along with other approved medications. Divozilimab is recombinant humanized anti-CD20 monoclonal antibody with a modified glycosylation pattern of Fc-fragment which is approved in Russian Federation for the treatment of multiple sclerosis, systemic scleroderma and also for NMOSD (September 2025). The publication is intended to present the results of the Russian Expert Councils work in September 2025 and February 2026. According to the analysis of publications on anti-CD20 NMOSD therapy, the 6-month results of divozilimab study BCD-132-6/AQUARELLE (NCT05730699) and data of additional subanalysis experts agreed the profiles of NMOSD patients for divozilimab therapy, time to full therapeutic effect and monitoring plan during treatment with divozilimab. Experts supplemented the algorithm for initial prescription and switching of medications for prevention of NMOSD attacks in patients with AQP4-IgG aged 18 years and older, agreed on the algorithm for the administration of medications for prevention of NMOSD attack in patients without AQP4-IgG aged 18 years and older, determined positions of divozilimab in both algorithms. According to experts opinion divozilimab appears as promising treatment option in NMOSD. Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.

  • Open Access

    Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial

    by Alexey N. Boyko, Mariya N. Zakharova, Taras O. Simaniv, Zoya A. Goncharova, Nikolay N. Spirin, Natalia A. Totolyan, Klara Z. Bakhtiyarova, Irina V. Greshnova, Vyacheslav A. Dudin, Denis S. Korobko, et al.

    Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.

  • Open Access

    Strokes and stroke risk factors in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) patients

    by Yu. M. Kyrianov, V. D. Nazarov, E. Yu. Vasilyeva, M. V. Kolegova, O. V. Sirotkina, S. V. Lapin, N. A. Totolyan, N. V. Shuleshova, Ю. М. Кирьянов

    Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is pointed out from the group of small vessel diseases and its main feature is considered to be the development of stroke in the absence of well-known cardiovascular stroke risk factors. Nevertheless, such comorbid factors can be present in CADASIL patients. 71 genetically confirmed CADASIL patients were observed, in 31 of whom, a complex investigation including clinical, laboratory, molecular genetic, instrumental and neurovisualization data was performed, and 60 were tested for the presence of variants of polymorphisms in thrombophilic genes to detect their possible significance in development of a cerebral vascular accident. Thrombophilic gene’s testing was also performed in comparison groups including 45 patients with lacunar or small strokes and/or cerebral microangiopathy, and 309 persons who underwent laboratory genetic testing to exclude thrombophilia of a reference group. The results showed presence in CADASIL patients such coexisting stroke risk factors as arterial hypertension in 61.3 %, dyslipidemia in 64.5 %, obesity in 22.6 %, diabetes mellitus in 12.9 %, and smoking in 35.5 %. Other comorbidities included cardiovascular dysfunction presented mainly by cardiac conductive disability in 81.8 %, the signs of connective tissue dysplasia in 50.0 %, migraine in 74.2 %, and autoimmune thyroiditis in 22.6 %. In 78.3% of CADASIL patients, the simultaneous presence of 2-4 pathological alleles was revealed, and the pathological variant 103 G>T in the activated coagulation factor XIII (F13A) (p<0.05) encoding fibrinase was more common compared to the the reference group, which requires further studies as additional non modifiable stroke risk factors in CADASIL patients.

  • Laboratory and instrumental diagnostics of chronic inflammatory demyelinating polyneuropathy: analysis of 158 cases

    by Ya. B. Kushnir, A. I. Bezvodinskikh, P. A. Kulagin, E. V. Bubnova, N. A. Totolyan

    Introduction. Given the diversity of clinical and electrophysiological phenotypes of chronic inflammatory demyelinating polyneuropathy (CIDP) and the variability of their response to disease-modifying therapy, immunopathological mechanisms likely differ across disease forms. Identifying key laboratory and instrumental features of various clinical and pathogenetic variants within the CIDP spectrum remains an important unmet need. The objective was to compare serum and cerebrospinal fluid (CSF) laboratory findings and instrumental study results in typical CIDP and its variants. Methods and materials. This retrospective-prospective study analyzed clinical, laboratory, and instrumental data from 158 patients with definite CIDP meeting the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria, stratified into typical CIDP and CIDP variants. Results. Anti-ganglioside and anti-sulfatide antibodies were most frequently detected in the sensory CIDP variant, in 46.2 % (12/26) of cases. Serum paraprotein was identified in 27.2 % (36/132) of patients; among these, a substantial proportion had the sensory variant – 33 % (12/36). When analyzing the structure of clinical phenotypes among patients screened for the presence of paraprotein (n=132), patients with the distal variant prevailed – 40% (8/20) of cases. The highest protein levels in the cerebrospinal fluid (CSF) were observed in patients with disease onset at the age of 15-29 years (Kruskal–Wallis test, p=0.028), as well as in patients with a relapsing type of course and acute onset (Pearson’s Chi-Square Test, p=0.01). No significant differences in CSF protein levels were found between typical CIDP and CIDP variants. Abnormal CSF oligoclonal IgG patterns were detected in 21.7 % (20/92) of patients and were observed significantly more often in CIDP variants, comprising 60.0 % (12/20) of such cases. According to electroneuromyography (ENMG) data, an increase in distal latency according to n. tibialis was significantly more often recorded in patients with typical CIDP compared with the variants (26.5% vs 7.3%, respectively; Pearson’s Chi-Square Test, p=0.0019). The analysis of cumulative indicators (Σ indicators) for n. tibialis also revealed a higher frequency of pathological changes in patients with typical CIDP (61.2% vs 35.8%; Pearson’s Chi-Square Test, p=0.0033). On magnetic resonance imaging (MRI), accumulation of contrast agent by nerve roots and cerebrospinal nerves was detected in 57.2 % (4/7) of patients with motor CIDP variant, which was significantly more often than in other disease variants (Fisher–Freeman–Halton test, p=0.006). Conclusion. In contemporary practice, laboratory and instrumental diagnostics in CIDP patients plays a critical role in excluding alternative causes of polyneuropathy. The identified laboratory and instrumental features across CIDP variants may be important not only for diagnosis but also for selecting optimal pathogenetic therapy.

  • Clinico-demographic characteristics and immunological cerebrospinal fluid markers in patients with headache and multiple sclerosis

    by N.M. Tereshchenko, V.S. Krasnov, N.A. Totolyan, E.V. Verbitskaya, A.V. Amelin

    Objective. To examine clinico-demographic characteristics, incidence and patterns of oligoclonal IgG in cerebrospinal fluid (CSF), concentrations of free light chains of immunoglobulin kappa (k-FLC), and total CSF protein in patients with multiple sclerosis (MS) with and without headache. Material and methods A retrospective single-center cohort study of patients with MS was performed between 2018 and 2024 at the Pavlov First St. Petersburg State Medical University. Medical records from 320 patients with MS were analyzed. Results. Among 320 patients with MS, 105 (32.8%) ones experienced headaches (H), including migraine (M) in 69 (21.6%), tension-type headache (TTH) in 19 (5.9%), and unclassified headache (UH) in 17 (5.3%) cases. M was more common in recurrent MS (19.1%) than in progressive MS (2.5%, p=0.006). TTH and UH did not demonstrate similar patterns. The incidence of type 2 IgG synthesis in CSF in the MS with M group was 79.31%, while in MS without headache — 64.42% (p=0.048). Levels of anti-FLC and total protein in CSF did not differ significantly between groups (p=0.395 and p=0.854, respectively). When comparing the incidence of type 2 IgG synthesis in CSF between groups for all headaches (M+TTH+ UH) and MS without headache, we found significant differences with higher incidence in the 1st group: 78.8% and 64.4%, respectively (p=0.021). Levels of anti-FLC and total protein in CSF were similar. Conclusion. Our data demonstrate high prevalence of M in patients with MS. Prevalence of M in remitting course of MS and high frequency of pathological synthesis of IgG in CSF in patients with any headache, and especially M, may indicate inflammatory mechanisms of headaches in some patients with MS. This justifies a prospective study on a large sample of patients with analysis of additional pathogenetically significant parameters.

  • Migraine in patients with multiple sclerosis: analysis of own data

    by N. M. Tereshchenko, A. V. Amelin, N. A. Totolyan, E. V. Verbitskaya

    Introduction. According to international publications, migraine (M) is more common in patients with multiple sclerosis (MS) than in the general population, while other types of primary headache (PH), including tension-type headache (TTH), do not have a similar tendency. There are several theories about the relationship between M and MS, but the substantiated mechanisms are currently unknown. The objective of our work was to analyze the data on the occurrence and characteristics of M in patients with MS. Methods and materials. A retrospective monocenter cohort study of patients with MS for the period 2018–2024 based on the Pavlov First Saint Petersburg State Medical University. Medical records of 168 patients with MS were analyzed. Results. The overall prevalence of PH in our cohort of patients was 36.9 %, including headache type M 22 %, TTH 6.6 %, unclassified headache (UH) 8.3 %, drug-induced headache (DIH) in the presence of any form of PH 6.5 %. M was significantly more common in the relapsing-remitting type of MS (RRMS) than in the primary and secondary progressive types (PPMS, SPMS) combined (p=0.031). The median EDSS (Expanded Disability Status Scale) disability scale in the group with M was 2 [2.0; 3.5], which is lower (p=0.046) than in the group of patients without headache 3.5 [2.0; 6.0]. Demographic characteristics and the use of disease-modifying drugs (DMARDS) did not differ significantly between the groups, and M was observed both before clinical manifestations of MS, at its manifestation, and developed after diagnosis. Conclusion. The obtained data demonstrate a high prevalence of M in MS. Patients predominantly with RRMS and a low level of disability represent a promising category for further study of the relationship between HD and demyelinating disease.

  • Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis

    by A.N. Boyko, V.M. Alifirova, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, G.N. Mishin, E.V. Parshina, I.YE. Poverennova, S.A. Sivertseva, et al.

    Objective. To assess the efficacy and safety of long-term treatment with divozilimab in patients with relapsing multiple sclerosis (MS). Material and methods. Study No. BCD-132-EXT enrolled patients with relapsing MS who had previously received divozilimab at a dose of 500 mg in a phase II and III studies. Taking into account the participation of patients in previous studies, the total treatment duration was 4 years. The efficacy assessment was carried out using parameters associated with relapses (annualized relapse rate (ARR), time to first relapse), parameters of magnetic resonance imaging of the brain, and also included evaluation of neurological deficit. Safety monitoring included evaluation of standard laboratory parameters and reporting of adverse events. Results. A total of 44 patients were enrolled in the study, of which 93.2% (41/44) patients completed 4 years of follow-up. During the BCD-132-EXT period, the proportion of relapse-free patients was 97.7%. Over the 4 years of observation, the ARR remained consistently low, with the overall ARR over 4 years of divozilimab treatment being 0.052 (95% CI 0.028; 0.097). The 6-month confirmed disability progression (CDP) during the treatment period was observed in 4.5% (n=2) of patients. Adverse reactions, most of which were mild to moderate in severity, were reported in 59.1% (n=26) of patients. The most common adverse reactions were decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, and infusion reactions. Conclusion. The obtained results indicate the maintenance of efficacy over 4 years of therapy with divozilimab. The safety profile of divozilimab was favorable and consistent with previously obtained data.


  • Neuropathic pain in chronic inflammatory demyelinating polyneuropathies: analysis of 64 cases

    by Ya.B. Kushnir, A.I. Bezvodinskikh, V.S. Krasnov, N.A. Totolyan, A.V. Amelin

    Objective. To characterize clinical phenotypes of CIDP with NP, identify possible associations between NP and laboratory parameters, and assess efficacy of pathogenetic and symptomatic therapy. Material and methods. A retrospective-prospective study included 158 patients with CIDP (2021 EAN/PNS criteria). Patients were divided into groups with and without NP, as well as further subcategorized by the timing of NP onset (at disease manifestation or during progression). Results. Neuropathic pain was identified in 64 (40.5%) patients with CIDP. In the NP group, females predominated (male/female ratio=1.21), whereas males were predominant in the non-NP group (male/female ratio = 0.57). There were significant differences in phenotypic structure of CIDP between patients with NP at disease onset, NP following disease progression and those without NP. Sensory variant of CIDP was more frequently associated with NP (50% of cases), while motor phenotype was less commonly associated with pain (6.25% of cases). In all patients with sensory variant of CIDP, NP was the first symptom of disease (n=27). We first analyzed transformation of CIDP phenotypes into typical form. Patients initially presenting with motor phenotype and subsequent NP more often progressed to typical CIDP. Serum paraprotein was more frequently detected in patients with NP (47.0% vs. 26.9% in those without NP). Positive antinuclear factor (ANF) titer (ANF ≥320) in NP patients was significantly associated with rheumatologic diseases. Conclusion. Clinical and laboratory characteristics in patients with neuropathic pain should be considered when selecting optimal therapy.

  • Open Access

    Clinical and immunological features of the pediatric multiple sclerosis

    by V. M. Lebedev, I. V. Kudryavtsev, M. A. Irikova, M. K. Serebriakova, N. A. Totolyan

    Introduction. The course of multiple sclerosis (MS) in children and adults has numerous differences, which may require the development of differentiated treatment approaches depending on the patient’s age. However, the pathogenetic basis of the above differences remains unclear. The objective was to evaluate the clinical features of pediatric MS and their relationship with the cytotoxic T-cell (Tcyt) subsets in peripheral blood.Methods and materials. The main group consisted of 33 patients with pediatric MS of adolescent age. In the main group and the comparison group of 22 adults with MS, clinical and MRI characteristics of the disease were assessed. In the main group, as well as in 28 adults with MS and 26 healthy adolescents, the main Tcyt subsets were identified, based on the expression of CD45RA and CD62L and co-expression of chemokine receptors CCR4, CCR6, CXCR3 and CXCR5.Results. The frequency of exacerbations and occurrence of highly active and rapidly progressing MS (HAMS) in pediatric MS was 1.5 times higher than in adults. An equivalent relationship between the severity of cerebellar disorders and HAMS was demonstrated both in the pediatric MS group and in adults. Adolescents with MS showed a significantly increased relative numbers of effector memory Tcyt expressing CCR6. For the first time, a relationship was determined between the effector Tcyt expressing CCR6 and highly active pediatric MS (p=0.04). A 2.5-fold increase of the relative numbers of CCR6-positive terminally differentiated Tcyt was found in patients with MRI activity compared to the patients in radiological remission (p=0.01). The results of ROC analysis showed high sensitivity (75.0 %) and specificity (89.7 %) of the CCR6+-positive effector memory Tcyt relative number in predicting the activity of the pediatric MS.Conclusions. The disability level has a significant relationship with the frequency of exacerbations in both pediatric MS patients and adults, and the frequency of exacerbations in pediatric MS patients during the first years of the disease is higher than in adults. The obtained results demonstrate a higher activity of T-cell component of the immune system in patients with pediatric MS compared to adults, in particular, various effector Tcyt subsets. The relative number of CCR6-positive effector memory Tcyt above 55.4 % can be considered as a prognostic marker of HAMS in pediatric MS.

  • Open Access

    Features of endocrine status in adolescents with multiple sclerosis

    by V. M. Lebedev, N. A. Totolyan

    Introduction. A number of authors have shown changes of hormonal status in adults with multiple sclerosis (MS) compared to healthy volunteers. At the same time, there are few such studies in the pediatric population, conducted on small groups, with ambiguous and contradictory results, which indicates the need for further research in this area.The objective was to determine the endocrine status features in adolescents with MS in comparison with healthy children and adult patients with MS, to assess the relationship between the levels of pituitary hormones, thyroid hormones, cortisol, sex hormones and the activity and severity of MS in adolescents and adults.Methods and materials. The main group consisted of 33 adolescent patients with pediatric MS, the comparison group included 22 adult patients with MS, and the control group comprised 26 healthy adolescents. All participants underwent assessments for the concentrations of prolactin, follicle-stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, thyroid-stimulating hormone, total and free thyroxine, triiodothyronine, cortisol, testosterone, dihydrotestosterone, estradiol, and 17-hydroxyprogesterone. In addition, clinical and MRI characteristics of the disease were evaluated in patients with MS.Results. Prolactin levels in adult and adolescent patients with MS were definitely higher than in a control group. Adolescents with higher cortisol levels at baseline showed a lower severity of motor dysfunction (r=–0.59, pConclusion. In adolescents and adults with MS, prolactin levels were significantly higher than in a control group of healthy adolescents. For the first time, a negative correlation between the baseline levels of endogenous steroid hormones and the degree of disability in several functional systems has been demonstrated in adolescents and adults. Changes in prolactin and 17-hydroxyprogesterone levels during MS exacerbation have been observed in adolescents, suggesting that both indicators may be potential targets for developing laboratory markers for disease reactivation.